首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >The role of gut microbiota in the pharmacokinetics of antihypertensive drugs
【24h】

The role of gut microbiota in the pharmacokinetics of antihypertensive drugs

机译:肠道微生物群在抗高血压药物药代动力学中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

The intestine is one of the most important sites for the metabolism of several xenobiotic compounds. In addition to intestinal drug-metabolizing enzymes and drug transporters, gut microbial enzymes modulate the biotransformation of orally administered drugs in the gastrointestinal tract. Antihypertensive drugs such as amlodipine and nifedipine could be metabolized by gut microbial enzymes, which may influence drug absorption, leading to changes in pharmacological potency of the drug and eventual failure of the appropriate blood pressure control or unexpected side effects. This may suggest that there are additional mechanisms that can alter the therapeutic efficacy of antihypertensive drugs, especially in certain pathological conditions of the gastrointestinal tract or with concomitant use of substances such as antibiotics and probiotics that might alter the gut microbial composition. This review describes the metabolism of antihypertensive drugs by hepatic and intestinal microbial enzymes in an attempt to understand the potential effects of gut microbiota on their pharmacokinetics. (C) 2018 Elsevier Ltd. All rights reserved.
机译:肠道是几种异蛋白化合物代谢最重要的位点之一。除了肠道药物代谢酶和药物转运蛋白之外,肠道微生物酶还调节口服给药中的生物转化在胃肠道中。可以通过肠道微生物酶代谢氨氯地脂和硝苯地平的抗高血压药物,这可能影响药物吸收,导致药物的药理效力的变化,并且可能发生适当的血压控制或意外的副作用。这可能表明存在额外的机制,可以改变抗高血压药物的治疗效果,尤其是在胃肠道的某些病理条件下或伴随可能改变肠道微生物组合物的抗生素和益生菌等物质。该综述描述了通过肝胃和肠道微生物酶的抗高血压药物的代谢,以试图了解肠道微生物会对其药代动力学的潜在影响。 (c)2018年elestvier有限公司保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号